Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Tufts Medical Center · University Medical Center Groningen · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
556
total citations
- FWCI
- 30.87
- Percentile
- 100%
- References
- 52
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Renal function
- Kidney disease
- Albuminuria
- Clinical trial
- Observational study
- Hazard ratio
- Creatinine
No related works found for this paper.
Funding
- AAstraZeneca
- BBayer
- MMerck
- NNovartis
- GSGilead Sciences
- APAlexion Pharmaceuticals
- AAbbVie
- TMTufts Medical Center
- BIBoehringer Ingelheim
- IPIronwood Pharmaceuticals, Incorporated
- APAstellas Pharma Canada
- KHKyowa Hakko Kirin
- NNNovo Nordisk
- SSiemens
- SServier
- IIpsen
- NINational Institutes of Health
- SGSanofi Genzyme
- RRelypsa